HomeOpen Access NewsSH - CytoSorbents Corporation

SH - CytoSorbents Corporation

Subscribe to Updates

Removal of inflammatory ‘evil humors’ – the key to treating COVID-19 complications?

Health & Social Care
Phillip P. Chan, MD, PhD, Chief Executive Officer of CytoSorbents Corporation (NASDAQ: CTSO), discusses the use of CytoSorb, a broad-spectrum blood purification technology to treat cytokine storm and hyperinflammation in critically ill COVID-19 patients.

No posts to display

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders

Visit Article Archive
Open Access Government

Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.

Follow Us

Resources

Quick Links

Legal & Marketing

As a Crossref Sponsored Member we are able to connect your content with a global network of online scholarly research, currently over 20,000 other organizational members from 160 countries. Crossref drive metadata exchange and support nearly 2 billion monthly API queries, facilitating global research communication.

© Adjacent Digital Politics Ltd